• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura touts data for Memspatch insulin micro-needle device

May 18, 2017 By Sarah Faulkner

Nemaura PharmaNemaura Pharma‘s Memspatch insulin micro-needle device compared well against a pen injector in an 18-patient clinical trials, according to the company.

The group of Type I diabetic patients were given insulin using either the Memspatch device or a traditional pen injector. Researchers evaluated the patient’s pain levels using a number pain rating score from 0 to 10. Patients were also asked to record their experiences with the devices and to reflect on the pain immediately following administration.

Pain intensity and sharpness reached 5 for several patients using the pen injector. Patients who used the Memspatch device reported a 0 or 1 when it was applied to the arm or thigh, according to Nemaura.

The Memspatch insulin delivery device administers insulin through shallow micro-needles, with skin-penetration kept to a depth of 2 millimeters to 4 millimeters. Pen injector needles often penetrate 9 millimeters into the skin.

“Needle phobia is a major barrier to health. We have looked carefully at the human factors restricting diabetics wanting to self-administer insulin, and have developed the Memspatch IMD to avoid puncture pain, and to improve treatment compliance,” CEO Faz Chowdhury said in prepared remarks. “Over 50% of adults with Type II diabetes delay starting insulin due to needle fear, and over 90% feel fear reactions every time they inject. So we would encourage the take-up of Memspatch IMD technology to help diabetics better manage their condition.”

The company is slated to evaluate its Memspatch device with other medicines later this year.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Nemaura Pharma

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS